Risk communication in consultations about hormone therapy in the menopause: concordance in risk assessment and framing due to the context

Author： Hoffmann M.   Hammar M.   Kjellgren K. I.   Lindh-Åstrand L.   Ahlner J.  

Publisher： Informa Healthcare

ISSN： 1473-0804

Source： Climacteric, Vol.9, Iss.5, 2006-10, pp. : 347-354

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hormone replacement therapy and prevention of osteoporosis: risk assessment and practical advice

By Balogh A.   Bettembuk P.  

European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 71, Iss. 2, 1997-02 ,pp. : 189-191

Elsevier

Access to resources Recommend Favorite

Osteoporosis risk factors: association with use of hormone replacement therapy and with worry about osteoporosis - the Framingham study

By Osborn B.H.   Couchman G.M.   Siegler I.C.   Bastian L.A.  

Women's Health Issues, Vol. 9, Iss. 6, 1999-11 ,pp. : 278-285

Elsevier

Access to resources Recommend Favorite

Is combined estrogen/progestogen hormone therapy worth the risk?

By Sturdee David W.   MacLennan Alastair H.  

Climacteric, Vol. 6, Iss. 3, 2003-09 ,pp. : 177-179

Informa Healthcare

Access to resources Recommend Favorite

Postmenopausal hormone therapy and the risk of venous thromboembolism

By Rachon D.   Teede H.  

Climacteric, Vol. 11, Iss. 4, 2008-01 ,pp. : 273-279

Informa Healthcare

Access to resources Recommend Favorite

Oral contraceptives, hormone therapy and cardiovascular risk

By Shapiro S.  

Climacteric, Vol. 11, Iss. 5, 2008-01 ,pp. : 355-363

Informa Healthcare

Access to resources Recommend Favorite